Cargando…
Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy
BACKGROUND: Gastric cancer (GC) is one of the leading causes of cancer-related death worldwide. The first-line treatment for GC is a combination of platinum and fluoropyrimidine-based therapy. Based on the positive results of RAINBOW and REGARD trials, ramucirumab either alone or in combination with...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613139/ https://www.ncbi.nlm.nih.gov/pubmed/36109437 http://dx.doi.org/10.1007/s12029-022-00865-5 |
_version_ | 1785128761284362240 |
---|---|
author | Roviello, Giandomenico Martina, Catalano Winchler, Costanza De Gennaro Aquino, Irene Papa, Francesca Buttitta, Eleonora Rossi, Gemma Antonuzzo, Lorenzo |
author_facet | Roviello, Giandomenico Martina, Catalano Winchler, Costanza De Gennaro Aquino, Irene Papa, Francesca Buttitta, Eleonora Rossi, Gemma Antonuzzo, Lorenzo |
author_sort | Roviello, Giandomenico |
collection | PubMed |
description | BACKGROUND: Gastric cancer (GC) is one of the leading causes of cancer-related death worldwide. The first-line treatment for GC is a combination of platinum and fluoropyrimidine-based therapy. Based on the positive results of RAINBOW and REGARD trials, ramucirumab either alone or in combination with paclitaxel has proved to be a safe and active option for second-line treatment in GC patients. MATERIAL AND METHODS: Advanced GC patients who received a 28-day cycles of ramucirumab and paclitaxel until disease progression or unacceptable toxicity were evaluated. Eligible patients had ECOG PS ≤ 1 and adequate organ function. Baseline characteristics were assessed for progression-free survival (PFS) and overall survival (OS). The Kaplan–Meier method and Cox proportional-hazards regression models were used for survival analyses. RESULTS: In our single institution experience, we included a total of 67 patients. A median OS of 8 months and a median PFS of 4 months, were recorded. In patients experiencing an initial partial response (PR), we observed a significant association between tumor response and survival outcomes (OS and PFS). The OS and PFS were 15 and 11 months in patients who experienced PR compared to 8 and 4 months in patients without PR (p = 0.02; p = 0.04). CONCLUSION: Treatment with ramucirumab plus paclitaxel yielded the highest overall response rate reported to date for patients with previously treated advanced GC. In our experience, the initial tumor response is associated with a greater survival benefit which could be further improved by the identification of biomarkers predicting response. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12029-022-00865-5. |
format | Online Article Text |
id | pubmed-10613139 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-106131392023-10-30 Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy Roviello, Giandomenico Martina, Catalano Winchler, Costanza De Gennaro Aquino, Irene Papa, Francesca Buttitta, Eleonora Rossi, Gemma Antonuzzo, Lorenzo J Gastrointest Cancer Original Research BACKGROUND: Gastric cancer (GC) is one of the leading causes of cancer-related death worldwide. The first-line treatment for GC is a combination of platinum and fluoropyrimidine-based therapy. Based on the positive results of RAINBOW and REGARD trials, ramucirumab either alone or in combination with paclitaxel has proved to be a safe and active option for second-line treatment in GC patients. MATERIAL AND METHODS: Advanced GC patients who received a 28-day cycles of ramucirumab and paclitaxel until disease progression or unacceptable toxicity were evaluated. Eligible patients had ECOG PS ≤ 1 and adequate organ function. Baseline characteristics were assessed for progression-free survival (PFS) and overall survival (OS). The Kaplan–Meier method and Cox proportional-hazards regression models were used for survival analyses. RESULTS: In our single institution experience, we included a total of 67 patients. A median OS of 8 months and a median PFS of 4 months, were recorded. In patients experiencing an initial partial response (PR), we observed a significant association between tumor response and survival outcomes (OS and PFS). The OS and PFS were 15 and 11 months in patients who experienced PR compared to 8 and 4 months in patients without PR (p = 0.02; p = 0.04). CONCLUSION: Treatment with ramucirumab plus paclitaxel yielded the highest overall response rate reported to date for patients with previously treated advanced GC. In our experience, the initial tumor response is associated with a greater survival benefit which could be further improved by the identification of biomarkers predicting response. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12029-022-00865-5. Springer US 2022-09-15 2023 /pmc/articles/PMC10613139/ /pubmed/36109437 http://dx.doi.org/10.1007/s12029-022-00865-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Research Roviello, Giandomenico Martina, Catalano Winchler, Costanza De Gennaro Aquino, Irene Papa, Francesca Buttitta, Eleonora Rossi, Gemma Antonuzzo, Lorenzo Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy |
title | Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy |
title_full | Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy |
title_fullStr | Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy |
title_full_unstemmed | Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy |
title_short | Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy |
title_sort | correlation between tumor response and survival outcomes in patients with advanced gastric cancer receiving ramucirumab and paclitaxel as second-line therapy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613139/ https://www.ncbi.nlm.nih.gov/pubmed/36109437 http://dx.doi.org/10.1007/s12029-022-00865-5 |
work_keys_str_mv | AT roviellogiandomenico correlationbetweentumorresponseandsurvivaloutcomesinpatientswithadvancedgastriccancerreceivingramucirumabandpaclitaxelassecondlinetherapy AT martinacatalano correlationbetweentumorresponseandsurvivaloutcomesinpatientswithadvancedgastriccancerreceivingramucirumabandpaclitaxelassecondlinetherapy AT winchlercostanza correlationbetweentumorresponseandsurvivaloutcomesinpatientswithadvancedgastriccancerreceivingramucirumabandpaclitaxelassecondlinetherapy AT degennaroaquinoirene correlationbetweentumorresponseandsurvivaloutcomesinpatientswithadvancedgastriccancerreceivingramucirumabandpaclitaxelassecondlinetherapy AT papafrancesca correlationbetweentumorresponseandsurvivaloutcomesinpatientswithadvancedgastriccancerreceivingramucirumabandpaclitaxelassecondlinetherapy AT buttittaeleonora correlationbetweentumorresponseandsurvivaloutcomesinpatientswithadvancedgastriccancerreceivingramucirumabandpaclitaxelassecondlinetherapy AT rossigemma correlationbetweentumorresponseandsurvivaloutcomesinpatientswithadvancedgastriccancerreceivingramucirumabandpaclitaxelassecondlinetherapy AT antonuzzolorenzo correlationbetweentumorresponseandsurvivaloutcomesinpatientswithadvancedgastriccancerreceivingramucirumabandpaclitaxelassecondlinetherapy |